Executive Summary
A single $253,723 firm-fixed-price contract to Lockheed Martin from NASA Goddard underscores neutral, low-materiality activity in space R&D for Mars end-to-end service architectures. The 3-month performance period (Mar-May 2026) with $0 outlays limits near-term revenue visibility and portfolio impact. This isolated award aligns with NASA's Mars focus but signals no broader trends warranting immediate position changes.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 01, 2026.
Investment Signals (1)
- NASA Mars R&D award to Lockheed (LOW)▲
$253k contract under full competition for Mars service architectures via PSC AR12.
Risk Flags (1)
- Execution [LOW RISK]▼
Firm-fixed-price terms shift cost overruns to contractor amid short 3-month period.
Opportunities (1)
- ◆
Alignment with NASA CIS Office's Mars capability studies BAA.
Sector Themes (1)
- ◆
Isolated small award highlights steady but low-dollar Mars research via open competition.
Watch List (1)
- 👁
{"entity"=>"Lockheed Martin", "reason"=>"New $253k NASA Mars R&D entry point amid zero outlays.", "trigger"=>"Outlays >10% of value or new awards >$1M in PSC AR12"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals